FANCA
FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Ovarian cancer and 5 more.
Overview
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Cisplatin. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes genetic literature 0.83, affected pathway 0.67, literature 0.95, genetic association 0.58, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Ovarian cancer and 5 more.
- 1 · What it is
FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Ovarian cancer and 5 more.
- 2 · What goes wrong in cancer
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.
- 3 · How drugs use it
No product in this corpus aims at FANCA yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:3582 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15360 (protein name, function text, keywords and locations (REST API)); CIViC gene FANCA (1 evidence items, 0 assertions, 1 variants; diseases: Prostate Cancer (GraphQL API, CC0)); Open Targets ENSG00000187741 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: colorectal cancer 0.50, gastric cancer 0.50, prostate cancer 0.52, ovarian cancer 0.60, melanoma 0.56, head and neck squamous cell carcinoma 0.52 (GraphQL API, CC0)); IntOGen FANCA (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Location: Nucleus; Cytoplasm (UniProt). Locus 16q24.3 (HGNC).
- Leukaemia: Open Targets association 0.64 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.61 with skin cancer (MONDO_0002898)
- Ovarian cancer: Open Targets association 0.60 with ovarian cancer (MONDO_0008170)
- Prostate cancer: Open Targets association 0.52 with prostate cancer (MONDO_0008315); CIViC evidence names this disease
- Myeloproliferative neoplasms: Open Targets association 0.56 with myeloproliferative neoplasm (MONDO_0020076)
- Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FANCA" OR ABSTRACT:"FANCA" OR TITLE:"FA complementation group A" OR ABSTRACT:"FA complementation group A" OR TITLE:"Fanconi anemia group A protein" OR ABSTRACT:"Fanconi anemia group A protein" OR TITLE:"FA-H" OR ABSTRACT:"FA-H" OR TITLE:"FANCH" OR ABSTRACT:"FANCH") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FANCA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetGATA2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetJAK3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetPOLD1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), CIViC.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetPIK3CB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetBCL6
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Lung cancer (all types), Skin cancer (all types), CIViC.
- TargetTERT
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).